TCG Crossover Amends KalVista Pharmaceuticals Stake

Ticker: KALV · Form: SC 13D/A · Filed: Feb 20, 2024 · CIK: 1348911

Kalvista Pharmaceuticals, Inc. SC 13D/A Filing Summary
FieldDetail
CompanyKalvista Pharmaceuticals, Inc. (KALV)
Form TypeSC 13D/A
Filed DateFeb 20, 2024
Risk Levellow
Pages6
Reading Time8 min
Key Dollar Amounts$0.001, $13.15, $14, $14.15
Sentimentneutral

Sentiment: neutral

Topics: insider-ownership, amendment, institutional-investor

TL;DR

**TCG Crossover just updated their stake in KalVista, signaling a change in their investment.**

AI Summary

TCG Crossover GP I, LLC, along with TCG Crossover Fund I, L.P. and Chen Yu, filed an Amendment No. 1 to their Schedule 13D for KalVista Pharmaceuticals, Inc. The filing, dated February 20, 2024, updates their beneficial ownership of KalVista's Common Stock, par value $0.001 per share. This amendment indicates a change in their previously reported holdings in the pharmaceutical company.

Why It Matters

This amendment signals a change in a significant investor's position in KalVista Pharmaceuticals, which could influence market perception and the company's stock performance.

Risk Assessment

Risk Level: low — This is an amendment to a Schedule 13D, indicating a change in beneficial ownership, which is a routine disclosure and not inherently high-risk.

Key Players & Entities

  • TCG Crossover GP I, LLC (company) — filer
  • TCG Crossover Fund I, L.P. (company) — group member
  • Chen Yu (person) — group member
  • KalVista Pharmaceuticals, Inc. (company) — subject company
  • $0.001 (dollar_amount) — par value per share

FAQ

Who filed this SC 13D/A amendment?

The SC 13D/A amendment was filed by TCG Crossover GP I, LLC, with TCG Crossover Fund I, L.P. and Chen Yu listed as group members.

What is the subject company of this filing?

The subject company of this filing is KalVista Pharmaceuticals, Inc.

What is the class of securities involved in this filing?

The class of securities involved is Common Stock, par value $0.001 per share, of KalVista Pharmaceuticals, Inc.

When was this amendment filed?

This Amendment No. 1 to Schedule 13D was filed on February 20, 2024.

What is the CIK of KalVista Pharmaceuticals, Inc.?

The Central Index Key (CIK) for KalVista Pharmaceuticals, Inc. is 0001348911.

Filing Stats: 1,928 words · 8 min read · ~6 pages · Grade level 8.6 · Accepted 2024-02-20 16:49:38

Key Financial Figures

  • $0.001 — me of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securiti
  • $13.15 — ple transactions at prices ranging from $13.15 to $14.14, inclusive. The Reporting Per
  • $14 — ctions at prices ranging from $13.15 to $14.14, inclusive. The Reporting Persons he
  • $14.15 — ple transactions at prices ranging from $14.15 to $14.50, inclusive. The Reporting Per

Filing Documents

From the Filing

SC 13D/A 1 d743893dsc13da.htm SC 13D/A SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* KALVISTA PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 483497 10 3 (CUSIP Number) Craig Skaling Chief Financial Officer TCG Crossover GP I, LLC 705 High St. Palo Alto, CA 94301 (650)-924-9424 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) February 7, 2024 (Date of Event Which Requires Filing of This Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. * The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act. CUSIP No. 483497 10 3 13D 1. Name of Reporting Persons TCG Crossover GP I, LLC 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a)(b) 3. SEC Use Only 4. Source of Funds (See Instructions) AF 5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) 6. Citizenship or Place of Organization Delaware Number of Shares Beneficially Owned by Each Reporting Person With 7. Sole Voting Power 0 8. Shared Voting Power 2,700,840 (1) 9. Sole Dispositive Power 0 10. Shared Dispositive Power 2,700,840 (1) 11. Aggregate Amount Beneficially Owned by Each Reporting Person 2,700,840 (1) 12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) 13. Percent of Class Represented by Amount in Row (11) 6.52% (2) 14. Type of Reporting Person (See Instructions) OO (1) These securities are held by TCG Crossover I (as defined in Item 2(a) below) and consist of (i) 2,518,370 shares of Common Stock (as defined in Item 1(a) below) and (ii) 182,470 shares of Common Stock underlying pre-funded warrants which are exercisable within 60 days of the date hereof. TCG Crossover GP I (as defined in Item 2(a) below) is the general partner of TCG Crossover I and may be deemed to have voting, investment, and dispositive power with respect to these securities. Chen Yu is the sole managing member of TCG Crossover GP I and may be deemed to share voting, investment and dispositive power with respect to these securities. (2) Based on 41,437,770 shares of the Issuers Common Stock outstanding (assuming the underwriters do not exercise the option to purchase additional shares), as disclosed by the Issuer in its prospectus supplement dated February 14, 2024 and filed with the Securities and Exchange Commission (the Commission) pursuant to Rule 424(b)(5) on February 16, 2024 (the Prospectus Supplement). CUSIP No. 483497 10 3 13D 1. Name of Reporting Persons TCG Crossover Fund I, L.P. 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a)(b) 3. SEC Use Only 4. Source of Funds (See Instructions) WC 5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) 6. Citizenship or Place of Organization Delaware Number of Shares Beneficially Owned by Each Reporting Person With 7. Sole Voting Power 0 8. Shared Voting Power 2,700,840 (1) 9. Sole Dispositive Power 0 10. Shared Dispositive Power 2,700,840 (1) 11. Aggregate Amount Beneficially Owned by Each Reporting Person 2,700,840 (1) 12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) 13. Percent of Class Represented by Amount in Row (11) 6.52% (2) 14. Type of Reporting Person (See Instructions) PN (1) These securities are held by TCG Crossover I and consist of (i) 2,518,370 shares of Common Stock and (ii) 182,470 shares of Common Stock underlying pre-funded warrants which are exercisable within 60 days of the date hereof. TCG Crossover GP I is the general partner of TCG Crossover I and may be deemed to have voting, investment, and dispositive power with respect to these securities. Chen Yu is the sole managing member of TCG Crossover GP I and may be deemed to share voting, investment and dispositive power with respect to these securities. (2) Based on 41,437,770 shares of the Issuers Common Stock outstanding (assuming the underwriters do not exercise t

View Full Filing

View this SC 13D/A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.